Alumis Stock Has Soared 400%. Cormorant Bought Another $8 Million Last Quarter

1 month ago 25

Jonathan Ponciano, The Motley Fool

Sun, May 17, 2026 astatine 1:33 PM CDT 4 min read

On May 15, 2026, Cormorant Asset Management disclosed a bargain of 313,645 shares of Alumis (NASDAQ:ALMS), with the estimated transaction worth astatine $7.84 cardinal based connected quarterly mean pricing.

What happened

According to a May 15, 2026 SEC filing, Cormorant Asset Management accrued its presumption successful Alumis by 313,645 shares during the archetypal quarter. The firm’s estimated commercialized size was $7.84 million, calculated utilizing the quarter’s mean closing price. The stake’s worth astatine quarter-end roseate by $51.52 million, a fig that incorporates some buying enactment and marketplace terms movements.

What other to cognize

Cormorant’s bargain brings its Alumis involvement to 4.37% of 13F assets arsenic of March 31, 2026.
Top holdings aft the filing:
- NASDAQ:PRAX: $285.30 cardinal (14.4% of AUM)
- NASDAQ:BBOT: $160.01 cardinal (8.1% of AUM)
- NASDAQ:EYPT: $106.54 cardinal (5.4% of AUM)
- NASDAQ:EWTX: $102.69 cardinal (5.2% of AUM)
- NASDAQ:ERAS: $93.84 cardinal (4.7% of AUM)
As of May 14, 2026, Alumis shares were priced astatine $24.63, up astir 400% implicit the past twelvemonth and vastly outperforming the S&P 500’s astir 25% summation successful the aforesaid period.

Company overview

Metric

Value

Price (as of marketplace adjacent May 14, 2026)	$24.63
Market Capitalization	$2.85 billion
Revenue (TTM)	$24.1 million
Net Income (TTM)	($243.3 million)

Company snapshot

Alumis develops clinical-stage biopharmaceutical products targeting autoimmune and neuroinflammatory diseases, including ESK-001 and A-005, with a absorption connected allosteric TYK2 inhibitors.
The institution operates a research-driven model, advancing proprietary cause candidates done objective trials.
It targets healthcare providers and pharmaceutical partners addressing autoimmune and neurodegenerative conditions, with a superior absorption connected the biotechnology and healthcare sectors.

Alumis is simply a clinical-stage biotechnology institution specializing successful the improvement of caller therapies for autoimmune and neuroinflammatory disorders. The institution leverages its expertise successful allosteric TYK2 inhibition to beforehand a pipeline of differentiated cause candidates. With a research-centric strategy and a absorption connected precocious unmet aesculapian needs, Alumis aims to found a competitory borderline successful the biopharmaceutical landscape.

What this transaction means for investors

This is 1 of respective buys Cormorant made past 4th into high-flying biotechs. With shares up astir 400% implicit the past year, the money added adjacent much exposure, signaling assurance that the company’s late-stage autoimmune pipeline could proceed driving upside from here.

A batch of that optimism centers astir envudeucitinib, Alumis’ oral TYK2 inhibitor for plaque psoriasis and lupus. Just past week, the institution reported beardown Phase 3 psoriasis information showing PASI 90 effect rates supra 60% and PASI 100 rates ofo astir 40% by Week 24, results absorption said enactment the drug’s imaginable arsenic a starring oral psoriasis therapy. Alumis besides said it remains connected way to taxable an NDA successful the 4th fourth of 2026, portion perchance pivotal lupus information are expected successful the 3rd quarter.

The equilibrium expanse besides gives the institution flexibility. Alumis ended March with astir $569.5 cardinal successful cash, currency equivalents, and marketable securities, which absorption says should money operations into precocious 2027.

As with its different buys (in Dianthus and Erasca), the accidental is clear, but truthful is the risk. Expectations are present highly precocious aft the stock’s monolithic run, meaning aboriginal objective information volition substance acold much than hype alone.

Read Entire Article